BioTelemetry, Inc. Agrees to License Proprietary Technology to Bloom Technologies, Inc. for Use in Prenatal Market
August 23 2016 - 8:15AM
BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical
technology company focused on the delivery of health information to
improve quality of life and reduce cost of care, is pleased to
announce that it has entered into a strategic partnership with
Bloom Technologies, Inc. (“Bloomlife”), an early stage digital
health company. Under the terms of the agreement, Bloomlife
will pay BioTelemetry a percentage of revenue to license their
proprietary telemetry technology to commercialize a consumer
oriented prenatal health sensor. This sensor will collect and
deliver a wide variety of prenatal data to expectant mothers that
can be shared with their healthcare providers.
Joseph H. Capper, President and Chief Executive Officer
of BioTelemetry, Inc., commented: “We are extremely excited to
partner with Bloomlife to expand the use of our proprietary
technology to the consumer-directed healthcare market. This
partnership advances our ongoing strategic commitment to identify
new markets that would benefit from the use of our
technology. Bloomlife’s novel use of BioTelemetry’s platform
will provide the necessary health information to positively impact
pregnancy outcomes with its future developments. We are proud
to partner with Bloomlife to improve the lives of expectant mothers
and their families.”
Eric Dy, Chief Executive Officer of Bloom Technologies, Inc.,
added: “We strive to take the guesswork out of pregnancy, easing
minds and providing actionable data to expectant mothers. We
believe the combination of our expertise and BioTelemetry’s
technology will help advance research aimed at the prevention of
pregnancy complications. We look forward to a long and successful
partnership with BioTelemetry.”
About BioTelemetryBioTelemetry, Inc., formerly
known as CardioNet, Inc., is the leading wireless medical
technology company focused on the delivery of health information to
improve quality of life and reduce cost of care. The company
currently provides cardiac monitoring services, original equipment
manufacturing with a primary focus on cardiac monitoring devices
and centralized cardiac core laboratory services. More
information can be found at www.gobio.com.
About BloomlifeBloomlife is a digital health
company focused on improving the health of moms and babies.
Bloomlife is developing technologies to measure physiological
signals known to impact pregnancy outcomes and to translate this
information into meaningful actionable information for women and
their care teams. Bloomlife aims to collect the largest
dataset on maternal and fetal health ever assembled and use this
data to resolve pregnancy complications such as gestational
diabetes, preeclampsia, and preterm birth. Find out more
at www.bloomlife.com.
Cautionary Statement Regarding Forward-Looking
Statements This document includes certain forward-looking
statements within the meaning of the “Safe Harbor” provisions of
the Private Securities Litigation Reform Act of 1995. These
statements may be identified by words such as “expect,”
“anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises”
and other words and terms of similar meaning. Such forward-looking
statements are based on current expectations and involve inherent
risks and uncertainties, including important factors that could
delay, divert, or change any of these expectations, and could cause
actual outcomes and results to differ materially from current
expectations. These factors include, among other things, our
ability to defend our patent portfolio and obtain favorable
results, effects of changes in health care legislation,
effectiveness of our cost savings initiatives, relationships with
our government and commercial payors, changes to insurance coverage
and reimbursement levels for our products, the success of our sales
and marketing initiatives, our ability to attract and retain
talented executive management and sales personnel, our ability to
identify acquisition candidates, acquire them on attractive terms
and integrate their operations into our business, the
commercialization of new products, market factors, internal
research and development initiatives, partnered research and
development initiatives, competitive product development, changes
in governmental regulations and legislation, the continued
consolidation of payors, acceptance of our new products and
services, patent protection, adverse regulatory action, litigation
success, our ability to successfully create a new holding company
structure and to anticipate the benefits of such structure. For
further details and a discussion of these and other risks and
uncertainties, please see our public filings with the Securities
and Exchange Commission, including our latest periodic reports on
Form 10-K and 10-Q. We undertake no obligation to publicly update
any forward-looking statement, whether as a result of new
information, future events, or otherwise.
Contact: BioTelemetry, Inc.
Heather C. Getz
Investor Relations
800-908-7103
investorrelations@biotelinc.com
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Sep 2023 to Sep 2024